Protein engineering to target complement evasion in cancer

FEBS Letters

Volumn 588, Issue 2, 2014, Pages 334-340

  Carter, Darrick ^a,b   Lieber, André ^c  

^a PAI Life Sciences   (United States)

^b Compliment Corp ^*  (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CD46; CD55; CD59; Complement inhibition; Tumor immune evasion

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B RECEPTOR; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; OFATUMUMAB; RITUXIMAB;

ANTIGEN BINDING; BINDING SITE; BLADDER CANCER; BREAST CANCER; CELL SURFACE; CELLULAR IMMUNITY; COLORECTAL CANCER; CYTOTOXICITY; ENZYME INHIBITION; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; HUMORAL IMMUNITY; LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TUMOR ESCAPE; UPREGULATION;

CD46; CD55; CD59; COMPLEMENT INHIBITION; TUMOR IMMUNE EVASION;

ANIMALS; COMPLEMENT SYSTEM PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN ENGINEERING; TRANSLATIONAL MEDICAL RESEARCH; TUMOR ESCAPE;

EID: 84892371035     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2013.11.007     Document Type: Review

References (90)

1. H. Chaplin Jr. Review: the burgeoning history of the complement system 1888-2005 Immunohematology 21 2005 85 93
2. R.B. Sim Complement, classical pathway J.D. Peter, Encyclopedia of Immunology second ed. 1998 Elsevier Oxford 604 612
3. K.T.P.W.M.J.C. Murphy Janeway's Immunobiology 2012 Garland Science New York
4. D. Spitzer, L.M. Mitchell, J.P. Atkinson, and D.E. Hourcade Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly J. Immunol. 179 2007 2600 2608
5. M.V. Carroll, and R.B. Sim Complement in health and disease Adv. Drug Deliv. Rev. 63 2011 965 975
6. D. Ricklin, G. Hajishengallis, K. Yang, and J.D. Lambris Complement: a key system for immune surveillance and homeostasis Nat. Immunol. 11 2010 785 797
7. S.E. Degn, and S. Thiel Humoral pattern recognition and the complement system Scand. J. Immunol. 78 2013 181 193
8. A.W. Dodds, X.D. Ren, A.C. Willis, and S.K. Law The reaction mechanism of the internal thioester in the human complement component C4 Nature 379 1996 177 179
9. I. Bally et al. Expression of recombinant human complement C1q allows identification of the C1r/C1s-binding sites Proc. Natl. Acad. Sci. USA 110 2013 8650 8655
10. M.C. Carroll The complement system in regulation of adaptive immunity Nat. Immunol. 5 2004 981 986
11. M.C. Carroll The complement system in B cell regulation Mol. Immunol. 41 2004 141 146
12. M.C. Carroll, and D.E. Isenman Regulation of humoral immunity by complement Immunity 37 2012 199 207
13. J.R. Dunkelberger, and W.C. Song Complement and its role in innate and adaptive immune responses Cell Res. 20 2010 34 50
14. J.R. Dunkelberger, and W.C. Song Role and mechanism of action of complement in regulating T cell immunity Mol. Immunol. 47 2010 2176 2186
15. C. Pomeroy, J. Mitchell, E. Eckert, N. Raymond, R. Crosby, and A.P. Dalmasso Effect of body weight and caloric restriction on serum complement proteins, including Factor D/adipsin: studies in anorexia nervosa and obesity Clin. Exp. Immunol. 108 1997 507 515
16. S. Ni Choileain, and A.L. Astier CD46 processing: a means of expression Immunobiology 217 2012 169 175
17. J.C. Marie, A.L. Astier, P. Rivailler, C. Rabourdin-Combe, T.F. Wild, and B. Horvat Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation Nat. Immunol. 3 2002 659 666
18. B. Sivasankar, M.P. Longhi, K.M.E. Gallagher, G.J. Betts, B.P. Morgan, A.J. Godkin, and A.M. Gallimore CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy? J. Immunol. 182 2009 5203 5207
19. S. Zeerleder C1-inhibitor: more than a serine protease inhibitor Semin. Thromb. Hemost. 37 2011 362 374
20. E. Makou, A.P. Herbert, and P.N. Barlow Functional anatomy of complement factor H Biochemistry 52 2013 3949 3962
21. S.C. Nilsson, R.B. Sim, S.M. Lea, V. Fremeaux-Bacchi, and A.M. Blom Complement factor I in health and disease Mol. Immunol. 48 2011 1611 1620
22. T. Masaki, M. Matsumoto, I. Nakanishi, R. Yasuda, and T. Seya Factor I-dependent inactivation of human complement C4b of the classical pathway by C3b/C4b receptor (CR1, CD35) and membrane cofactor protein (MCP, CD46) J. Biochem. 111 1992 573 578
23. T. Hofmeyer et al. Arranged sevenfold: structural insights into the C-terminal oligomerization domain of human C4b-binding protein J. Mol. Biol. 425 2013 1302 1317
24. K.T. Preissner Structure and biological role of vitronectin Annu. Rev. Cell Biol. 7 1991 275 310
25. L. Mesnard et al. Vitronectin dictates intraglomerular fibrinolysis in immune-mediated glomerulonephritis FASEB J. 25 2011 3543 3553
26. A.K. Chauhan, and T.L. Moore Presence of plasma complement regulatory proteins clusterin (Apo J) and vitronectin (S40) on circulating immune complexes (CIC) Clin. Exp. Immunol. 145 2006 398 406
27. D. Liu, and Z.-X. Niu The structure, genetic polymorphisms, expression and biological functions of complement receptor type 1 (CR1/CD35) Immunopharmacology and Immunotoxicology 31 2009 524 535 10.3109/ 08923970902845768
28. M.L. Barilla-LaBarca, M.K. Liszewski, J.D. Lambris, D. Hourcade, and J.P. Atkinson Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells J. Immunol. 168 2002 6298 6304
29. J. Cardone et al. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells Nat. Immunol. 11 2010 862 871
30. A. Nicholson-Weller, J. Burge, D.T. Fearon, P.F. Weller, and K.F. Austen Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system J. Immunol. 129 1982 184 189
31. E.D. Vainer, K. Meir, M. Furman, I. Semenenko, F. Konikoff, and G.W. Vainer Characterization of novel CD55 isoforms expression in normal and neoplastic tissues Tissue Antigens 82 2013 26 34
32. M.E. Medof, T. Kinoshita, and V. Nussenzweig Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes J. Exp. Med. 160 1984 1558 1578
33. F.C. Kimberley, B. Sivasankar, and B. Paul Morgan Alternative roles for CD59 Mol. Immunol. 44 2007 73 81
34. I. Farkas et al. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9 J. Physiol. 539 2002 537 545
35. S.K. Blick, and L.J. Scott Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer Drugs 67 2007 2585 2607
36. G. Nightingale Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia Ann. Pharmacother. 45 2011 1248 1255
37. M. Pegram, and J. Liao Trastuzumab treatment in multiple lines: current data and future directions Clin. Breast Cancer 12 2012 10 18
38. G. Von Minckwitz, S. Loibl, and M. Untch What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer? Oncology (Williston Park) 26 2012 20 26
39. N. Di Gaetano et al. Complement activation determines the therapeutic activity of rituximab in vivo J. Immunol. 171 2003 1581 1587
40. J. Golay et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes Haematologica 91 2006 176 183
41. M.E. Reff et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 1994 435 445
42. B. Bellosillo, N. Villamor, A. Lopez-Guillermo, S. Marce, J. Esteve, E. Campo, D. Colomer, and E. Montserrat Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species Blood 98 2001 2771 2777
43. L.E. van der Kolk, A.J. Grillo-Lopez, J.W. Baars, C.E. Hack, and M.H. van Oers Complement activation plays a key role in the side-effects of rituximab treatment Br. J. Haematol. 115 2001 807 811
44. K.A. Gelderman, S. Tomlinson, G.D. Ross, and A. Gorter Complement function in mAb-mediated cancer immunotherapy Trends Immunol. 25 2004 158 164
45. A. Gorter, and S. Meri Immune evasion of tumor cells using membrane-bound complement regulatory proteins Immunol. Today 20 1999 576 582
46. P. Macor, and F. Tedesco Complement as effector system in cancer immunotherapy Immunol. Lett. 111 2007 6 13
47. J. Golay, M. Lazzari, V. Facchinetti, S. Bernasconi, G. Borleri, T. Barbui, A. Rambaldi, and M. Introna CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 Blood 98 2001 3383 3389
48. P. Macor, C. Tripodo, S. Zorzet, E. Piovan, F. Bossi, R. Marzari, A. Amadori, and F. Tedesco In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab Cancer Res. 67 2007 10556 10563
49. P. Macor, D. Mezzanzanica, C. Cossetti, P. Alberti, M. Figini, S. Canevari, and F. Tedesco Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma Cancer Res. 66 2006 3876 3883
50. G.A. Niehans, D.L. Cherwitz, N.A. Staley, D.J. Knapp, and A.P. Dalmasso Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin) Am. J. Pathol. 149 1996 129 142
51. L. Thorsteinsson, G.M. O'Dowd, P.M. Harrington, and P.M. Johnson The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues Apmis 106 1998 869 878
52. Z. Madjd, L. Durrant, S. Pinder, I. Ellis, J. Ronan, S. Lewis, N. Rushmere, and I. Spendlove Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)? Cancer Immunol. Immunother. 54 2005 149 156
53. R.D. Loberg, K.J. Wojno, L.L. Day, and K.J. Pienta Analysis of membrane-bound complement regulatory proteins in prostate cancer Urology 66 2005 1321 1326
54. J.C. Varela, C. Atkinson, R. Woolson, T.E. Keane, and S. Tomlinson Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection Int. J. Cancer 123 2008 1357 1363
55. K.P. Murray, S. Mathure, R. Kaul, S. Khan, L.F. Carson, L.B. Twiggs, M.G. Martens, and A. Kaul Expression of complement regulatory proteins - CD35, CD46, CD55, and CD59 - in benign and malignant endometrial tissue Gynecol. Oncol. 76 2000 176 182
56. N.M.H. Ravindranath, and C. Shuler Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas J. Oral Pathol. Med. 35 2006 560 567
57. K. Shimo et al. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma J. Gastroenterol. Hepatol. 19 2004 643 647
58. J. Dzietczenia, T. Wróbel, G. Mazur, R. Porȩba, B. Jaźwiec, and K. Kuliczkowski Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20(+) non-Hodgkin's lymphoma Med. Oncol. 27 2010 743 746
59. W.-K. Weng, and R. Levy Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma Blood 98 2001 1352 1357
60. F. Guzzo et al. HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas Int. J. Gynecol. Pathol. 31 2012 211 221
61. E. Cocco et al. Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor Clin. Exp. Metastasis 28 2011 689 700
62. J.L. Teeling et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20 J. Immunol. 177 2006 362 371
63. B. Zhang Ofatumumab MAbs 1 2009 326 331
64. G.L. Moore, H. Chen, S. Karki, and G.A. Lazar Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions MAbs 2 2010 181 189
65. W.R. Strohl Optimization of Fc-mediated effector functions of monoclonal antibodies Curr. Opin. Biotechnol. 20 2009 685 691
66. E.E. Idusogie, P.Y. Wong, L.G. Presta, H. Gazzano-Santoro, K. Totpal, M. Ultsch, and M.G. Mulkerrin Engineered antibodies with increased activity to recruit complement J. Immunol. 166 2001 2571 2575
67. N. Geis, S. Zell, R. Rutz, W. Li, T. Giese, S. Mamidi, S. Schultz, and M. Kirschfink Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro Curr. Cancer Drug Targets 10 2010 922 931
68. R.D. Loberg, L.L. Day, R. Dunn, L.M. Kalikin, and K.J. Pienta Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo Neoplasia 8 2006 69 78
69. F. Ziller, P. Macor, R. Bulla, D. Sblattero, R. Marzari, and F. Tedesco Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59 Eur. J. Immunol. 35 2005 2175 2183
70. H. Nagamune, C. Ohnishi, A. Katsuura, K. Fushitani, R.A. Whiley, A. Tsuji, and Y. Matsuda Intermedilysin, a novel cytotoxin specific for human cells secreted by Streptococcus intermedius UNS46 isolated from a human liver abscess Infect. Immun. 64 1996 3093 3100
71. S. Johnson, N.J. Brooks, R.A. Smith, S.M. Lea, and D. Bubeck Structural basis for recognition of the pore-forming toxin intermedilysin by human complement receptor CD59 Cell Rep. 3 2013 1369 1377
72. W. Hu et al. A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS J. Immunol. 184 2010 359 368
73. L. Wu et al. Removal of the tag from His-tagged ILYd4, a human CD59 inhibitor, significantly improves its physical properties and its activity Curr. Pharm. Des. 18 2012 4187 4196
74. W. Hu et al. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis Cancer Res. 71 2011 2298 2307
75. X. Ge, L. Wu, W. Hu, S. Fernandes, C. Wang, X. Li, J.R. Brown, and X. Qin RILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia Clin. Cancer Res. 17 2011 6702 6711
76. A. Gaggar, D. Shayakhmetov, and A. Lieber CD46 is a cellular receptor for group B adenoviruses Nat. Med. 9 2003 1408 1412
77. H. Wang et al. Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob J. Virol. 81 2007 12785 12792
78. S. Tuve et al. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells J. Virol. 80 2006 12109 12120
79. Z. Wang, C.S. Kuhr, J.M. Allen, M. Blankinship, P. Gregorevic, J.S. Chamberlain, S.J. Tapscott, and R. Storb Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression Mol. Ther. 15 2007 1160 1166
80. H. Wang et al. In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46 J. Virol. 82 2008 10567 10579
81. H. Wang, Y. Liu, Z.Y. Li, X. Fan, A. Hemminki, and A. Lieber A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy Blood 115 2010 592 600
82. I. Beyer et al. Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques Mol. Ther. 21 2013 291 299
83. E.O. Saphire, R.L. Stanfield, M.D. Max Crispin, P.W.H.I. Parren, P.M. Rudd, R.A. Dwek, D.R. Burton, and I.A. Wilson Contrasting IgG structures reveal extreme asymmetry and flexibility J. Mol. Biol. 319 2002 9 18
84. E.E. Idusogie, L.G. Presta, H. Gazzano-Santoro, K. Totpal, P.Y. Wong, M. Ultsch, Y.G. Meng, and M.G. Mulkerrin Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc J. Immunol. 164 2000 4178 4184
85. N. Guex, and M.C. Peitsch SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling Electrophoresis 18 1997 2714 2723
86. 2004 Persistence of Vision Raytracer (Version 3.6) (Ltd., P.o.V.P., ed.eds).
87. C.M. Fabry, M. Rosa-Calatrava, J.F. Conway, C. Zubieta, S. Cusack, R.W. Ruigrok, and G. Schoehn A quasi-atomic model of human adenovirus type 5 capsid EMBO J. 24 2005 1645 1654
88. R. Hanson Jmol - a paradigm shift in crystallographic visualization J. Appl. Crystallogr. 43 2010 1250 1260
89. B.D. Persson, D.M. Reiter, M. Marttila, Y.F. Mei, J.M. Casasnovas, N. Arnberg, and T. Stehle Adenovirus type 11 binding alters the conformation of its receptor CD46 Nat. Struct. Mol. Biol. 14 2007 164 166
90. M.J. van Raaij, A. Mitraki, G. Lavigne, and S. Cusack A triple beta-spiral in the adenovirus fibre shaft reveals a new structural motif for a fibrous protein Nature 401 1999 935 938